Patent details
301080
Product Name:
indacaterolacetaat of indacaterolxinafoaat, bij voorkeur
indacaterolacetaat, in combinatie met mometasonfuroaat en
glycopyrronium
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
301080
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2044025
Status:
Application Pending
Application number:
301080
Procedural language:
Dutch
First Applicant Residence Country:
Switzerland (CH)
Marketing Authorization
1
Marketing Authorization Number:
EU/1/20/1440
Marketing Authorization Type:
EEA
Marketing Authorization Date:
06/07/2020
Marketing Authorization Country:
European Union (EU)
2
Marketing Authorization Number:
EU/1/20/1438
Marketing Authorization Type:
EEA
Marketing Authorization Date:
06/07/2020
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
16/12/2020
First Marketing Authorization date:
06/07/2020
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
17/12/2020
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
Applicant/holder
From:
16/12/2020
Name:
Novartis AG
Address:
Lichtstrasse 35, 4056, BASEL, Switzerland (CH)
Agent
1
Name:
ir. B.Ch. Ledeboer c.s
From:
09/01/2025
Address:
V.O.
Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:
2
Name:
ir. H.A. Witmans c.s.
From:
16/12/2020
Address:
V.O.
Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:
09/01/2025
Publication
Bulletin
Bulletin Heading:
SPC
Journal edition number:
52/20
Publication date:
23/12/2020
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date
Document type
Document Description
Number of pages
File Type
17/12/2020
Outgoing Correspondence
Confirmation receipt request
1
PDF
/4/2/2/5/3/0800635224/docs/301080_12_384939l174.pdf
16/12/2020
SPC Documents
Annex SPC
29
PDF
/4/2/2/5/3/0800635224/docs/301080_0_supplprotectioncertificate20201217101658988.pdf
16/12/2020
SPC Documents
Annex SPC
28
PDF
/4/2/2/5/3/0800635224/docs/301080_1_supplprotectioncertificate20201217102028756.pdf
16/12/2020
Application Form
First filed application form
3
PDF
/4/2/2/5/3/0800635224/docs/301080_2_applicationform20201217095708235.pdf
16/12/2020
SPC Documents
Accompanying letter SPC
3
PDF
/4/2/2/5/3/0800635224/docs/301080_3_supplprotectioncertificate20201217100144697.pdf
16/12/2020
SPC Documents
Annex SPC
2
PDF
/4/2/2/5/3/0800635224/docs/301080_4_supplprotectioncertificate20201217101909913.pdf
16/12/2020
SPC Documents
Annex SPC
10
PDF
/4/2/2/5/3/0800635224/docs/301080_5_supplprotectioncertificate20201217101058858.pdf
16/12/2020
SPC Documents
Marketing Authorization SPC
3
PDF
/4/2/2/5/3/0800635224/docs/301080_6_supplprotectioncertificate20201217100305697.pdf
16/12/2020
SPC Documents
Summary of the characteristics of the product
25
PDF
/4/2/2/5/3/0800635224/docs/301080_7_supplprotectioncertificate20201217101248774.pdf
16/12/2020
SPC Documents
Annex SPC
2
PDF
/4/2/2/5/3/0800635224/docs/301080_8_supplprotectioncertificate20201217100752001.pdf
16/12/2020
SPC Documents
Annex SPC
2
PDF
/4/2/2/5/3/0800635224/docs/301080_9_supplprotectioncertificate20201217101501435.pdf
16/12/2020
SPC Documents
Summary of the characteristics of the product
25
PDF
/4/2/2/5/3/0800635224/docs/301080_10_supplprotectioncertificate20201217101816552.pdf
16/12/2020
SPC Documents
Marketing Authorization SPC
3
PDF
/4/2/2/5/3/0800635224/docs/301080_11_supplprotectioncertificate20201217100638899.pdf